You are here

Gene Correction in SCD-iPSCs

A new STEM CELLS Translational Medicine article led by Naoya Uchida (National Institutes of Health, Bethesda, MD, USA) describes the successful correction of the sickle mutation in induced pluripotent stem cells derived from a patient with sickle cell disease (SCD). Haro‐Mora et al. employed an improved serum‐free technique that included the generation of induced pluripotent stem cell‐sacs, a hemangioblast‐like structure containing hematopoietic stem and progenitor cells that can be differentiated into erythroid cells containing mostly definitive globins.